CD274 and hepatocellular carcinoma: Although immune checkpoint blockade (ICB) therapies targeting the PD-1/PD-L1 axis have demonstrated clinical promise in advanced HCC, therapeutic responses remain heterogeneous, underscoring the need to elucidate the mechanisms governing PD-L1 expression.